SCHEMBL796453

SCHEMBL796453

CN(c1ccccc1)c1nc(N)nc(-c2noc(C3CNC3)n2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.34
NR1H4 Q96RI1 1/20 0.34
MAPK1 P28482 2/20 0.34
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
GRM5 P41594 2/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
MAPT P10636 2/20 0.32
CNR2 P34972 1/20 0.32
TLR9 Q9NR96 1/20 0.32
TLR8 Q9NR97 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL796105 0.99 DHFR (0.34) DHFRNR1H4MAPK1ALDH1A1NPC1
Hydrochloric Acid SCHEMBL15477120 0.91 NR1H4 (0.40) DHFRNR1H4MAPK1ALDH1A1NPC1
Hydrochloric Acid SCHEMBL795905 0.88 NR1H4 (0.47) DHFRNR1H4MAPK1ALDH1A1NPC1
SCHEMBL12467074 0.87 NPC1 (0.49) MAPK1ALDH1A1NPC1TP53RAB9A
SCHEMBL795462 0.86 NPC1 (0.38) DHFRNR1H4MAPK1ALDH1A1NPC1
SCHEMBL795636 0.86 NPC1 (0.38) DHFRNR1H4MAPK1ALDH1A1NPC1
SCHEMBL796432 0.85 TLR9 (0.36) DHFRNR1H4MAPK1ALDH1A1NPC1
SCHEMBL796433 0.85 TLR9 (0.36) DHFRNR1H4MAPK1ALDH1A1NPC1
SCHEMBL795712 0.85 NPC1 (0.37) MAPK1ALDH1A1NPC1TP53RAB9A
SCHEMBL807924 0.84 NAMPT (0.39) DHFRMAPK1ALDH1A1NPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 EP disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 DHFR 1553/4885NR1H4 393/4885MAPK1 3234/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 DHFR 1553/4885NR1H4 393/4885MAPK1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.